Pre-therapy serum albumin-to-globulin ratio in patients treated with neoadjuvant chemotherapy and radical nephroureterec
- PDF / 1,064,344 Bytes
- 11 Pages / 595.276 x 790.866 pts Page_size
- 82 Downloads / 169 Views
ORIGINAL ARTICLE
Pre‑therapy serum albumin‑to‑globulin ratio in patients treated with neoadjuvant chemotherapy and radical nephroureterectomy for upper tract urothelial carcinoma Benjamin Pradere1,2 · David D’Andrea1 · Victor M. Schuettfort1 · Beat Foerster3 · Fahad Quhal1,4 · Keiichiro Mori1,5 · Mohammad Abufaraj6 · Vitaly Margulis7 · Marine Deuker8,9 · Alberto Briganti10 · Tim Muilwijk11 · Kees Hendricksen12 · Yair Lotan13 · Pierre Karakiewic9 · Shahrokh F.Shariat1,13,14,15,16,17,18 · For the UTUC collaboration Received: 21 July 2020 / Accepted: 1 October 2020 © The Author(s) 2020
Abstract Purpose The accurate selection of patients who are most likely to benefit from neoadjuvant chemotherapy is an important challenge in oncology. Serum AGR has been found to be associated with oncological outcomes in various malignancies. We assessed the association of pre-therapy serum albumin-to-globulin ratio (AGR) with pathologic response and oncological outcomes in patients treated with neoadjuvant platin-based chemotherapy followed by radical nephroureterectomy (RNU) for clinically non-metastatic UTUC. Methods We retrospectively included all clinically non-metastatic patients from a multicentric database who had neoadjuvant platin-based chemotherapy and RNU for UTUC. After assessing the pretreatment AGR cut‐off value, we found 1.42 to have the maximum Youden index value. The overall population was therefore divided into two AGR groups using this cut‐off (low,
